NCT02962063 2025-09-05
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT02571725 2025-05-23
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1/2 Active not recruiting
NCT03837899 2024-10-29
Durvalumab and Tremelimumab for Pediatric Malignancies
AstraZeneca
Phase 1/2 Active not recruiting
NCT03784066 2024-07-03
DUTRELASCO
Universitaire Ziekenhuizen KU Leuven
Phase 1/2 Active not recruiting
NCT03283605 2024-06-28
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 1/2 Active not recruiting